Tag Archives: Technion

National Stamp Marks 100 years of Technion

Leave a comment
Israeli post gets smart with the Technion Centennial Stamp

The Israel Postal Company’s Philatelic Service is issuing a stamp celebrating the 100th anniversary of the cornerstone laying ceremony in Haifa of the Technion.


The new stamp will be unveiled as part of the Technion’s centennial activities, which will be launched on Tuesday President, Prof. Peretz Lavie, Haifa Mayor Yona Yahav and the postal authorities. 


The stamp shows a sketch of the old Technion building’s plans and the image of a nano parachute developed at the Technion at the lab of Prof. Eyal Zussman.  The Nanofiber technology recently led to the establishment of a prize-winning new company, NanoSpun through the T3 Technion Technology Transfer office. 


The Technion was Israel’s first academic institution and is today one of the most prominent in its field, Postal Company board chairman Sasii Shilo told the Jerusalem Post.


Ubiquitin gets ubiquitous through the post… Technion’s first Nobel Laureates in Chemistry were also honored last year by a stamp released to celebrate their discovery. Read the full story here.

National Stamp Marks 100 years of Technion

Leave a comment
Israeli post gets smart with the Technion Centennial Stamp

The Israel Postal Company’s Philatelic Service is issuing a stamp celebrating the 100th anniversary of the cornerstone laying ceremony in Haifa of the Technion.


The new stamp will be unveiled as part of the Technion’s centennial activities, which will be launched on Tuesday President, Prof. Peretz Lavie, Haifa Mayor Yona Yahav and the postal authorities. 


The stamp shows a sketch of the old Technion building’s plans and the image of a nano parachute developed at the Technion at the lab of Prof. Eyal Zussman.  The Nanofiber technology recently led to the establishment of a prize-winning new company, NanoSpun through the T3 Technion Technology Transfer office. 


The Technion was Israel’s first academic institution and is today one of the most prominent in its field, Postal Company board chairman Sasii Shilo told the Jerusalem Post.


Ubiquitin gets ubiquitous through the post… Technion’s first Nobel Laureates in Chemistry were also honored last year by a stamp released to celebrate their discovery. Read the full story here.

Nobel Prize Winning Ubiquitin in Action

1 Comment
Proteologics’ pioneers targeted drug development CEO Joshua Levin discusses the molecules being developed with Teva and GlaxoSmithKline.[Extracted from Globes, Israel]

The award of the 2011 Nobel Prize in Chemistry to Prof. Dan Schechtman, following the 2009 win by Prof. Ada Yonath, put the world of chemistry and Israel’s contributions to science that laypeople can barely understand in the limelight. Schechtman and Yonath have not yet turned their discoveries, of quasi-crystals and the mechanism of the ribosome, respectively, into commercial products, but their two Israeli predecessors, Prof. Aaron Ciechanover and Prof. Avram Hershko, the 2004 Nobel Laureates in Chemistry, have succeeded in doing so (or at least trying). They contributed their know-how and reputations to Proteologics Ltd. (TASE: PRTL).

Ubiquitin – the new buzzword

To understand what Proteologics is doing, it is necessary to go back to high school chemistry and the stubborn teacher who tried to explain what a protein is. The company is developing targeted therapeutics for the ubiquitin system, which regulates almost all aspects of eukaryotic cellular function, including cell cycle regulation, DNA repair, signal transduction, immune response, protein quality control and metabolism. The system comprises about 1,000 protiens.
Hershko and Ciechanover discovered the ubiquitin system in 1978, and jointly won the Nobel Prize in Chemistry in 2004 for the discovery. They are both members of Proteologics’ science advisory board.
Targeted medications are not regular drugs; as their name implies, they have just one specific target, and are consequently more effective, (improving a patient’s quality of life by reducing the side effects of treatment) and are more efficient for health funds by cutting costs. These drugs discover the proteins that play an important role in a disease, neutralizing which leads to improvement, even a cure, for the disease in question.
A ubiquitin is a small regulatory protein that can be attached to proteins and label them for destruction for the proper function of the cell. Ubiquitin tags can also direct proteins to other locations in the cell, where they control other protein and cell mechanisms. Disruption of the ubiquitin system is therefore liable to cause a wide range of diseases, including cancers, diseases of the nervous system such as Alzheimer’s or Parkinson’s, muscular dystrophy, and viral diseases.
Drug development is complicated, and the difficulties are compounded in the case of the ubiquitin system. It is a hierarchal cascade system with three levels: The E1 enzyme is a single protein, which can bind with the subordinate level, E2 enzymes (of which there are about 40), which in turn influence the more than 600 E3 enzymes.
This hierarchal cascade and the multiple E2-E3 connections complicates the drug development task. E3 enzymes directly transfer the signal to the protein, and this is where Proteologics finds the proteins that are the basis for its therapeutics. Any intervention higher up in the hierarchy is liable to cause harm rather than help.
Business model: spread the risk
Proteologics’ business model may prove in future to be much more effective than the models of other R&D companies. The drug development and approval process has three main stages. First is identification of the target and development of a suitable molecule, which is followed by preclinical and human clinical trials.
Proteologics only operates at the first and second stages, while the final stage, which requires more time and financial investment, is handled by the company’s big pharma partners – Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) and GlaxoSmithKline plc (NYSE; LSE: GSK).
In this way, Proteologics reduces its financial risk, as the clinical trial and most expensive stage is carried out by big pharma companies which bear the financial risk. Proteologics even receives advances for R&D costs, which are partly covered by its partners. The company also has an option for receiving milestone payments, and will receive generous royalties from sales, assuming that the drug is approved for marketing.
Until that day comes, if it ever does, Proteologics can use the milestone payments to pursue additional projects on the basis of the platform it developed for working with E3 enzymes with different tags. This enables the company to survive, in theory, for a long time as it expands its knowledge and its platform to create a large enough product base that will increase its chances of turning at least one of its drug candidates into a commercial product.
Proteologics CEO Joshua Levin says that it has been able to lower its risk profile by choosing two partners that complements each other, in both character and terms of the agreements signed with them. GlaxoSmithKline, a UK giant with a market cap of $117 billion, is developing with Proteologics six programs for the treatment of various cancers (each program is based on a different E3 enzyme). Teva is jointly developing three programs. Proteologics is also developing two programs independently, and will either continue to do so or find a partner.
“GlaxoSmithKline and Teva complement each other,” says Levin. “Teva is not an innovative company, which is why it chose to invest a little in us now, and give us a larger share of revenue from drug sales. GlaxoSmithKline, in contrast, chose to invest much more in us at the first and second stages, and took a greater share for itself when the drug reaches market.”
In the case of GlaxoSmithKline, which is the more important partner for Levin, each program could generate up to $176 million in royalties, or up to $1 billion altogether, but Levin is realistic about these numbers. “This isn’t a real number. There’s no chance that all six drugs will be commercialized,” he says.

2012 is the critical year

Under Proteologics’ timetable, 2012 will be a critical year. Teva, which has undergone quite a few changes, mainly as a result of its acquisition of Cephalon, is scheduled to receive its first molecule from Proteologics within months, and will have to decide whether it wants to pursue development. If it chooses not to do so, Proteologics can continue development (a Phase I clinical trial) independently, or find another partner, without the need to start the development process from scratch.
Levin is not worried that either Teva or GlaxoSmithKline will return molecules to the company, but he is nonetheless doing everything to make sure that does not happen. In the case of GlaxoSmithKline, each program has a three-year timeframe, which means that in early 2013, Proteologics will have to hand over the first molecule to it and wait for a response.
Read full article at Globes

Nobel Prize Winning Ubiquitin in Action

1 Comment
Proteologics’ pioneers targeted drug development CEO Joshua Levin discusses the molecules being developed with Teva and GlaxoSmithKline.[Extracted from Globes, Israel]

The award of the 2011 Nobel Prize in Chemistry to Prof. Dan Schechtman, following the 2009 win by Prof. Ada Yonath, put the world of chemistry and Israel’s contributions to science that laypeople can barely understand in the limelight. Schechtman and Yonath have not yet turned their discoveries, of quasi-crystals and the mechanism of the ribosome, respectively, into commercial products, but their two Israeli predecessors, Prof. Aaron Ciechanover and Prof. Avram Hershko, the 2004 Nobel Laureates in Chemistry, have succeeded in doing so (or at least trying). They contributed their know-how and reputations to Proteologics Ltd. (TASE: PRTL).

Ubiquitin – the new buzzword

To understand what Proteologics is doing, it is necessary to go back to high school chemistry and the stubborn teacher who tried to explain what a protein is. The company is developing targeted therapeutics for the ubiquitin system, which regulates almost all aspects of eukaryotic cellular function, including cell cycle regulation, DNA repair, signal transduction, immune response, protein quality control and metabolism. The system comprises about 1,000 protiens.
Hershko and Ciechanover discovered the ubiquitin system in 1978, and jointly won the Nobel Prize in Chemistry in 2004 for the discovery. They are both members of Proteologics’ science advisory board.
Targeted medications are not regular drugs; as their name implies, they have just one specific target, and are consequently more effective, (improving a patient’s quality of life by reducing the side effects of treatment) and are more efficient for health funds by cutting costs. These drugs discover the proteins that play an important role in a disease, neutralizing which leads to improvement, even a cure, for the disease in question.
A ubiquitin is a small regulatory protein that can be attached to proteins and label them for destruction for the proper function of the cell. Ubiquitin tags can also direct proteins to other locations in the cell, where they control other protein and cell mechanisms. Disruption of the ubiquitin system is therefore liable to cause a wide range of diseases, including cancers, diseases of the nervous system such as Alzheimer’s or Parkinson’s, muscular dystrophy, and viral diseases.
Drug development is complicated, and the difficulties are compounded in the case of the ubiquitin system. It is a hierarchal cascade system with three levels: The E1 enzyme is a single protein, which can bind with the subordinate level, E2 enzymes (of which there are about 40), which in turn influence the more than 600 E3 enzymes.
This hierarchal cascade and the multiple E2-E3 connections complicates the drug development task. E3 enzymes directly transfer the signal to the protein, and this is where Proteologics finds the proteins that are the basis for its therapeutics. Any intervention higher up in the hierarchy is liable to cause harm rather than help.
Business model: spread the risk
Proteologics’ business model may prove in future to be much more effective than the models of other R&D companies. The drug development and approval process has three main stages. First is identification of the target and development of a suitable molecule, which is followed by preclinical and human clinical trials.
Proteologics only operates at the first and second stages, while the final stage, which requires more time and financial investment, is handled by the company’s big pharma partners – Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) and GlaxoSmithKline plc (NYSE; LSE: GSK).
In this way, Proteologics reduces its financial risk, as the clinical trial and most expensive stage is carried out by big pharma companies which bear the financial risk. Proteologics even receives advances for R&D costs, which are partly covered by its partners. The company also has an option for receiving milestone payments, and will receive generous royalties from sales, assuming that the drug is approved for marketing.
Until that day comes, if it ever does, Proteologics can use the milestone payments to pursue additional projects on the basis of the platform it developed for working with E3 enzymes with different tags. This enables the company to survive, in theory, for a long time as it expands its knowledge and its platform to create a large enough product base that will increase its chances of turning at least one of its drug candidates into a commercial product.
Proteologics CEO Joshua Levin says that it has been able to lower its risk profile by choosing two partners that complements each other, in both character and terms of the agreements signed with them. GlaxoSmithKline, a UK giant with a market cap of $117 billion, is developing with Proteologics six programs for the treatment of various cancers (each program is based on a different E3 enzyme). Teva is jointly developing three programs. Proteologics is also developing two programs independently, and will either continue to do so or find a partner.
“GlaxoSmithKline and Teva complement each other,” says Levin. “Teva is not an innovative company, which is why it chose to invest a little in us now, and give us a larger share of revenue from drug sales. GlaxoSmithKline, in contrast, chose to invest much more in us at the first and second stages, and took a greater share for itself when the drug reaches market.”
In the case of GlaxoSmithKline, which is the more important partner for Levin, each program could generate up to $176 million in royalties, or up to $1 billion altogether, but Levin is realistic about these numbers. “This isn’t a real number. There’s no chance that all six drugs will be commercialized,” he says.

2012 is the critical year

Under Proteologics’ timetable, 2012 will be a critical year. Teva, which has undergone quite a few changes, mainly as a result of its acquisition of Cephalon, is scheduled to receive its first molecule from Proteologics within months, and will have to decide whether it wants to pursue development. If it chooses not to do so, Proteologics can continue development (a Phase I clinical trial) independently, or find another partner, without the need to start the development process from scratch.
Levin is not worried that either Teva or GlaxoSmithKline will return molecules to the company, but he is nonetheless doing everything to make sure that does not happen. In the case of GlaxoSmithKline, each program has a three-year timeframe, which means that in early 2013, Proteologics will have to hand over the first molecule to it and wait for a response.
Read full article at Globes

How start-ups get started. Israel, NYC & TCII

Leave a comment
Silicon Island: a NYC hub for technology transfer

“We are glad to have the opportunity to join forces with Cornell University, to tap into the already rich innovative New York based eco-system and share our tech-transfer practices, insights and methodologies”

One of the most significant global academic milestones of this century must be the decision announced on December 19th 2011 by New York Mayor Bloomberg of Cornell University and Technion-Israel Institute of Technology as winners in a $2 billion competition to build a science and engineering campus on Roosevelt Island. The planned campus aims to serve 2,500 students and 280 faculty by 2043. It also intends to boost the number of graduate engineering students in the area by 70 percent. For the first time in history, the new academic venture will be called an institute of “Innovation”.

For Technion scientists patenting new technologies and looking at commercialization, TCII represents a foothold in New York City which is vital for global commercialization and networking. US investors will also have a domestic gateway to emerging technologies from Israel’s top powerhouse of innovation.

Included in plans for TCII (the Technion Cornell Institute of Innovation), is a $150 million fund to spawn New York area startups. The move comes on the heels of plans from IBM, Intel and others to participate in a $4.4 billion New York state effort to develop semiconductor technology for 450mm wafers.

“The message we are sending with this announcement is: look out Silicon Valley, look out Boston, New York will be second to none,” stated U.S. Senator Charles E. Schumer.

The campus will be organized around three interdisciplinary hubs: Connective Media, Healthier Life, and the Built Environment. Cornell will immediately offer Master and Doctoral degrees in areas such as Computer Science, Electrical and Computer Engineering, and Information Science and Engineering. In addition, after receiving the required accreditation, the campus will also offer innovative Technion-Cornell dual Master of Applied Sciences degrees. The concept of organizing TCII into multidiciplinary ‘hubs’ was introduced by the Technion, based on its successful multidisciplinary research centers, such as the Grand Technion Energy Program, says Technion President Peretz Lavie.

The TCII Campus will host entrepreneurs-in-residence, organize business competitions, provide legal support for startups, reach out to existing companies to form research partnerships and sponsor research, and establish a pre-seed financing program to support promising research. In addition, the campus will structure its tech transfer office, which will be on-site, to facilitate startup formation and technology licensing. The TCII Campus will also establish a $150 million revolving financing fund that will be solely devoted to start-up businesses in new York City.

“Starting today, we are going to put our plan to work, tapping into our extensive connections throughout the city and build a truly 21st Century campus to fuel the creation of new businesses and new industries throughout the city for decades to come.

“Technology Transfer activity takes place at the Technion in many shapes and forms resulting in significant economic development both locally and nationally,” says manager of the Technion Technology Transfer Office ( T3 ) Benjamin Soffer. “We are glad to have the opportunity to join forces with Cornell University, tap into the already rich innovative New York based eco-system and share our tech-transfer practices, insights  and methodologies to the benefit of the state of New York and the US at large.” 

IP (intellectual property) coming out of the TCII will be held jointly by Cornell University and Technion.

According to Israel’s Ministry of Foreign Affairs, Technion has a world-class track-record in research, development and entrepreneurship. The Technion’s departments of Electrical Engineering and Computer Science are considered among the best in the world. It  boasts top ranking faculty members including Nobel laureates. The Technion has long been considered a driving force behind Israel’s emergence as one of the world’s great centers of technology.

“Israel’s heros used to be the generals; now, the heros are the entrepreneurs.”

Technion  T3 Manager Benjamin Soffer,

Israel today has one of the highest concentrations of high-tech start-up companies globally. In partnership with a strong community of incubators, private investors, venture capitalists, angel groups and entrepreneurs, the Technion’s tech transfer arm, Technion Technology Transfer ( T3 ), has filed an average of 300 new patents each year and annually nurtures innovative startups in sectors such as clean-tech, cell therapy, drug delivery, nanotechnology and others. Companies including Intel, Google, Microsoft, IBM, Qualcomm, Broadcom, Yahoo! and Hewlett-Packard have established major operations near or on the Technion campus. Only this month, Apple announced that it will be joining the others to set up a ground-breaking R&D Center near Technion City – to be headed by Technion graduate Aharon Aharon.

Technion graduates currently head nearly half of the 121 Israeli companies on the NASDAQ, which have a combined market value of over $28 billion. More than 70 percent of the Technion graduates are employed in the high technology sectors that drive Israel’s economic growth.  Presently, Israeli companies headed by the Technion graduates employ 85 percent of Israel’s technical workforce.  According to a recent article in the Israeli newspaper Haaretz, there are approximately 4,000 start-up companies located around the Technion’s home campus.

President Lavie addresses press. NYC, 19th December, 2011

With the selection of Cornell/Technion now complete, the project is scheduled to move into the environmental and land use review process, expected to be completed by the fall of 2013. Groundbreaking on the first phase of the Roosevelt Island campus is expected by the beginning of 2015. A temporary off-site campus will be open in 2012.

NYC – Technion-Cornell Cornerstone of the Future

Leave a comment
NYC Tech Campus:
“Our greatest strength is our diversity. This is the day we really do usher in the high tech economy.”


Technion President Peretz Lavie

“No more faculties but HUBS that are flexible, overlapping and interact with industry: an open very flexible system built around themes rather than traditional fields of science.
…We found a partner, and what a partner. A program of innovation. We are not going to have an extension of the Technion or Cornell but something new that will really energize this city. 
…The links between Technion and New York go back to the 1910s, with a donation from US philanthropist Jacob Schiff….
…The Technion was founded in 1912…100 years later we come to New York to close the historic circle. We are building the bridge between Israel and the US, Technion and Cornell, New York and Haifa.” 

...from Jaffa oranges to semiconductors

…I just came from Stockholm… this is as exciting as a Nobel”

Cornell President David J. Skorton:
“A story of connectivity, between people and their ideas, between teachers and their students…
…Success needs technology,innovation, entrepreneurial ecosystem…
…We need to extend the talent pool… and retain them in NYC – as many as possible for as long as possible.”
New campius: “An environmental standard bearer.”
Mayor Bloomberg:

 “Today will be remembered as a defining moment.”

“A dynamic joint submission from two world class institutions”

“The economic impact will be greater than we thought. A game changer.”

“Transformative, cutting edge campus, pioneering green elements…”

The bid- “The most students, faculty, building space, environmentally sustainable”

“The element includes elements to integrate the campus with the city… “

“Unprecedented fund for start ups with high dividends”

“Technion sits at the center of an ecosystem of startups + hightech giants”

“3/4 nobel scientists in Israel came from Technion – “

 Technion – Cornell: “A tantalizing groundbreaking partnership.”

“Cornell Tech campus will spin out more than 600 new companies over 30 yrs”

“The courage to expand… their success will be our success”
They are calling the Technion Israel’s version of MIT. This is very flattering, but there is a difference. Technion was founded in 1912 – decades before the birth of the State of Israel. It was the inculcation of expert skills, creativity and pioneering ingenuity among young people that facilitated the birth of a nation. You can check the Technion’s unique history on Wikipedia, or view it rapidly in the video below! If you want it in a different language, go to Technion Channel and take your pick!
100 years ago, the first cornerstone was laid for Israel’s 1st university. So much was embodied in that cornerstone, including the realization of the hopes, dreams and genius of a people who had been disenfranchised for centuries. The original charter of the Technion was not only Zionist. It was to bring skills, education and training to people denied access to higher education in the service of all humanity.
In 2012, in the year of the Technion’s cornestone centenary, a third millennium cornerstone is to be laid, on that realized the vision to be of service to all humankind. United with Cornell University – an institution unrivaled in its creativity, standards of excellence and flair for innovation, Technion will be working to establish the foundations of the global village of tomorrow – a center of higher education that will transform the New York of the coming 100 years – bringing innovation, employment and creativity, introducing tomorrows generation of medicine, life sciences, nanotechnology, software, electronics and  global entrepreneurship.
At Technion, tomorrow begins today.
The path of progress. Technion & Cornell link up
to announce the bid for NYC ‘genius’ tech campus

Unconstrained by geography… the Technion – Cornell link-up
to generate innovation at the heart of the global village.

Green, clean and aesthetic… artists impression of the new
campus on Roosevelt Island.

A coalition to lay the scientific and technological foundations
of tomorrow’s world.

Cornell President Skorton in a video conference with
Technion President Peretz Lavie.

NYC – Technion-Cornell Cornerstone of the Future

Leave a comment
NYC Tech Campus:
“Our greatest strength is our diversity. This is the day we really do usher in the high tech economy.”


Technion President Peretz Lavie

“No more faculties but HUBS that are flexible, overlapping and interact with industry: an open very flexible system built around themes rather than traditional fields of science.
…We found a partner, and what a partner. A program of innovation. We are not going to have an extension of the Technion or Cornell but something new that will really energize this city. 
…The links between Technion and New York go back to the 1910s, with a donation from US philanthropist Jacob Schiff….
…The Technion was founded in 1912…100 years later we come to New York to close the historic circle. We are building the bridge between Israel and the US, Technion and Cornell, New York and Haifa.” 

...from Jaffa oranges to semiconductors

…I just came from Stockholm… this is as exciting as a Nobel”

Cornell President David J. Skorton:
“A story of connectivity, between people and their ideas, between teachers and their students…
…Success needs technology,innovation, entrepreneurial ecosystem…
…We need to extend the talent pool… and retain them in NYC – as many as possible for as long as possible.”
New campius: “An environmental standard bearer.”
Mayor Bloomberg:

 “Today will be remembered as a defining moment.”

“A dynamic joint submission from two world class institutions”

“The economic impact will be greater than we thought. A game changer.”

“Transformative, cutting edge campus, pioneering green elements…”

The bid- “The most students, faculty, building space, environmentally sustainable”

“The element includes elements to integrate the campus with the city… “

“Unprecedented fund for start ups with high dividends”

“Technion sits at the center of an ecosystem of startups + hightech giants”

“3/4 nobel scientists in Israel came from Technion – “

 Technion – Cornell: “A tantalizing groundbreaking partnership.”

“Cornell Tech campus will spin out more than 600 new companies over 30 yrs”

“The courage to expand… their success will be our success”
They are calling the Technion Israel’s version of MIT. This is very flattering, but there is a difference. Technion was founded in 1912 – decades before the birth of the State of Israel. It was the inculcation of expert skills, creativity and pioneering ingenuity among young people that facilitated the birth of a nation. You can check the Technion’s unique history on Wikipedia, or view it rapidly in the video below! If you want it in a different language, go to Technion Channel and take your pick!
100 years ago, the first cornerstone was laid for Israel’s 1st university. So much was embodied in that cornerstone, including the realization of the hopes, dreams and genius of a people who had been disenfranchised for centuries. The original charter of the Technion was not only Zionist. It was to bring skills, education and training to people denied access to higher education in the service of all humanity.
In 2012, in the year of the Technion’s cornestone centenary, a third millennium cornerstone is to be laid, on that realized the vision to be of service to all humankind. United with Cornell University – an institution unrivaled in its creativity, standards of excellence and flair for innovation, Technion will be working to establish the foundations of the global village of tomorrow – a center of higher education that will transform the New York of the coming 100 years – bringing innovation, employment and creativity, introducing tomorrows generation of medicine, life sciences, nanotechnology, software, electronics and  global entrepreneurship.
At Technion, tomorrow begins today.
The path of progress. Technion & Cornell link up
to announce the bid for NYC ‘genius’ tech campus

Unconstrained by geography… the Technion – Cornell link-up
to generate innovation at the heart of the global village.

Green, clean and aesthetic… artists impression of the new
campus on Roosevelt Island.

A coalition to lay the scientific and technological foundations
of tomorrow’s world.

Cornell President Skorton in a video conference with
Technion President Peretz Lavie.

Israel: Land of the Little Apple

Leave a comment




High-tech Giant Apple to set up Israel development center

With Technion graduates heading R&D centers for Microsoft, Yahoo, Google and Intel to name a view, Apple has until now been noticeable by it absence. Now, news is surfacing that Technion graduate (first and second degrees) Aharon Aharon will head Apple’s first ever development center outside of its California headquarters.

 
Apple Inc. has decided to open a development center in Israel focusing on semiconductors, the first R&D venture for the company outside the United States, the Israeli Business news service Globes Wednesday. The decision was apparently made even before the company entered into talks to acquire Herzliya-based flash storage solutions provider Anobit Ltd.

Apple has hired Aharon Aharon, Technion graduate and a veteran player in Israel’s high tech industry, to lead the new development center. The planned Israel center will be the company’s first such center outside of its California headquarters.

Aharon Aharon comes to Apple with a rich background. His most high-tech venture was Camero Tech Ltd., which develops Radio Frequency (RF) based imaging systems, and which he founded in 2004 with Amir Beeri. Before that, he was chairman of embedded security solutions developer Discretix Inc. and managed their Israel development center. He was also VP operations at Zoran Corp.(Nasdaq: ZRAN), having begun his career at IBM’s Haifa development center where he reached the post of deputy director.

Apple is cultivating it;s new orchard for future growth fast. Aharon will be spending some months at Apple HQ in Cupertino before launching the Israel enterprise and harvesting the local skills and ingenuity. It is one ground breaking decision that is sure to support Apple in maintaining its competitive edge in the next, even smarter generation.

The Birth of Super Resolution – Technion Startup in HD!

Leave a comment

A clear-cut example of the dynamic process of technology transfer at the Technion – the startup BETTERview is slated to revolutionize the quality of HD imaging – by taking and applying new research from the Technion department of electrical engineering all the way to your the screen of your TV, PC or smart phone. Have something old and cloudy? BETTERvIew also offers a conversion service to produce images as crisp as if they were filmed with the cutting-edge cameras of tomorrow.


BETTERView offers SD to true HD (High Definition) conversion and video enrichment. Check the following video to see the quality advantage.




The patented breakthrough in the super resolution promises to breaks the “glass ceiling” of existing technology, says the company, whose team includes world-experts from Technion’s Faculty of Computer Science, which is ranked #15 in the world. While conventional methods use conversion techniques to “blow up” or stretch the SD video onto an HD display, BetterVirw increases optical resolution of a video stream, generating an HD stream that looks as authentic as it gets.


BETTERview technology is based on a novel family of SR algorithms, proposed by a world-leader in this field, Prof. Michael Elad (Technion – Israel Institute of Technology). Elad and his collaborator, Dr. Matan Protter devised the first method that overcomes the requirement for very accurate and explicit motion estimation in previous SR technologies. The new family of SR techniques avoids the exact motion estimation and replaces it by a probabilistic estimate. This enables handling successfully general content scenes containing extremely complex motion patterns. 


The results are impressive, with no visual artifacts, and the process is completely robust. Based on this core technology, BETTERview developed the first cutting-edge industrial-grade robust system that perform SD to True HD resolution conversion. Its solution strengthens the above-mentioned core technology by handling various video artifacts, interlaced content, synchronization issues and run-time efficiency.


The innovative research of Prof. Michael Elad was listed in 2010 by Thomson Reuters Science Watch. You can read their interview with him here.



It has been known for the past 20 years that, in principle, one could take several low-quality images and fuse them into a single, higher-resolution outcome. This has been demonstrated by scientists, adopting various techniques and algorithms. The process is known as Super-Resolution (SR), which  became a hot field in image processing, with thousands of academic papers published during the past two decades on the problem and ways to handle it. The classical approach to fuse the low-quality images requires finding an exact correspondence between their pixels, a process known as “motion estimation”. Several years ago this field experienced a revolution, due to a breakthrough in the way to handle (or better yet, bypass altogether) the motion estimation. 

The Birth of Super Resolution – Technion Startup in HD!

Leave a comment

A clear-cut example of the dynamic process of technology transfer at the Technion – the startup BETTERview is slated to revolutionize the quality of HD imaging – by taking and applying new research from the Technion department of electrical engineering all the way to your the screen of your TV, PC or smart phone. Have something old and cloudy? BETTERvIew also offers a conversion service to produce images as crisp as if they were filmed with the cutting-edge cameras of tomorrow.


BETTERView offers SD to true HD (High Definition) conversion and video enrichment. Check the following video to see the quality advantage.




The patented breakthrough in the super resolution promises to breaks the “glass ceiling” of existing technology, says the company, whose team includes world-experts from Technion’s Faculty of Computer Science, which is ranked #15 in the world. While conventional methods use conversion techniques to “blow up” or stretch the SD video onto an HD display, BetterVirw increases optical resolution of a video stream, generating an HD stream that looks as authentic as it gets.


BETTERview technology is based on a novel family of SR algorithms, proposed by a world-leader in this field, Prof. Michael Elad (Technion – Israel Institute of Technology). Elad and his collaborator, Dr. Matan Protter devised the first method that overcomes the requirement for very accurate and explicit motion estimation in previous SR technologies. The new family of SR techniques avoids the exact motion estimation and replaces it by a probabilistic estimate. This enables handling successfully general content scenes containing extremely complex motion patterns. 


The results are impressive, with no visual artifacts, and the process is completely robust. Based on this core technology, BETTERview developed the first cutting-edge industrial-grade robust system that perform SD to True HD resolution conversion. Its solution strengthens the above-mentioned core technology by handling various video artifacts, interlaced content, synchronization issues and run-time efficiency.


The innovative research of Prof. Michael Elad was listed in 2010 by Thomson Reuters Science Watch. You can read their interview with him here.



It has been known for the past 20 years that, in principle, one could take several low-quality images and fuse them into a single, higher-resolution outcome. This has been demonstrated by scientists, adopting various techniques and algorithms. The process is known as Super-Resolution (SR), which  became a hot field in image processing, with thousands of academic papers published during the past two decades on the problem and ways to handle it. The classical approach to fuse the low-quality images requires finding an exact correspondence between their pixels, a process known as “motion estimation”. Several years ago this field experienced a revolution, due to a breakthrough in the way to handle (or better yet, bypass altogether) the motion estimation.